Literature DB >> 10984139

Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis.

M Meissner1, Y Sherer, Y Levy, H Chwalinska-Sadowska, P Langevitz, Y Shoenfeld.   

Abstract

The use of intravenous immunoglobulin (IVIg) has been reported as an immunomodulating agent in several autoimmune diseases, including systemic lupus erythematosus (SLE). Herein we report a SLE patient with severe clinical presentation that included pericarditis, pleural effusion, nephrotic range proteinuria, leukopenia, and lymphopenia. The patient received one course of high-dose IVIg (2.8 g/kg body weight), and within a week of post-IVIg therapy, her condition significantly improved. One-month post-IVIg there were decreased proteinuria, elevated leukocytes and lymphocytes count, decrease in antinuclear and anti-dsDNA antibodies, and disappearance of pericarditis and pleuritis. This case demonstrates the efficacy of IVIg in severe SLE with various clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984139     DOI: 10.1007/s002960000053

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  8 in total

Review 1.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Intravenous immunoglobulin in treatment of cardiac tamponade in a patient with systemic lupus erythematosus.

Authors:  Tal Grenader; Linda Shavit
Journal:  Clin Rheumatol       Date:  2004-12       Impact factor: 2.980

3.  Intravenous immunoglobulin therapy leading to dramatic improvement in a patient with systemic juvenile idiopathic arthritis and severe pericarditis resistant to steroid pulse therapy.

Authors:  Tomomi Aizawa-Yashiro; Eishin Oki; Kazushi Tsuruga; Tohru Nakahata; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2010-03-18       Impact factor: 2.631

Review 4.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

5.  Clinical applications of immunoglobulin: update.

Authors:  Marcia Cristina Zago Novaretti; Carla Luana Dinardo
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 6.  Indications for IVIG in rheumatic diseases.

Authors:  Ben Mulhearn; Ian N Bruce
Journal:  Rheumatology (Oxford)       Date:  2014-11-17       Impact factor: 7.580

7.  Intravenous immunoglobulin in the management of lupus nephritis.

Authors:  Scott E Wenderfer; Trisha Thacker
Journal:  Autoimmune Dis       Date:  2012-09-27

8.  IVIG ameliorate inflammation in collagen-induced arthritis: projection for IVIG therapy in rheumatoid arthritis.

Authors:  G Halpert; I Katz; M Blank; O Shovman; S Tarasov; K K Ganina; N Petrova; M Tocut; A Volkov; I Barshack; H Amital
Journal:  Clin Exp Immunol       Date:  2020-10-26       Impact factor: 5.732

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.